Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAB-001 in Mild to Moderate Alzheimer's Disease
NCT00174525Phase 2Unknown
- Sponsor
- Pharmacology Research Institute
- Start
- Apr 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing AAB-001 with Placebo (2 arms). Primary endpoint: Safety assessments. Status: unknown.
02
Drugs
bapineuzumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00174525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00174525.